These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
79 related articles for article (PubMed ID: 20405848)
1. Design, synthesis, and interaction study of quinazoline-2(1H)-thione derivatives as novel potential Bcl-xL inhibitors. Feng Y; Ding X; Chen T; Chen L; Liu F; Jia X; Luo X; Shen X; Chen K; Jiang H; Wang H; Liu H; Liu D J Med Chem; 2010 May; 53(9):3465-79. PubMed ID: 20405848 [TBL] [Abstract][Full Text] [Related]
2. Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis. Petros AM; Dinges J; Augeri DJ; Baumeister SA; Betebenner DA; Bures MG; Elmore SW; Hajduk PJ; Joseph MK; Landis SK; Nettesheim DG; Rosenberg SH; Shen W; Thomas S; Wang X; Zanze I; Zhang H; Fesik SW J Med Chem; 2006 Jan; 49(2):656-63. PubMed ID: 16420051 [TBL] [Abstract][Full Text] [Related]
3. Structure-activity relationship studies of ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (HA 14-1), an antagonist for antiapoptotic Bcl-2 proteins to overcome drug resistance in cancer. Doshi JM; Tian D; Xing C J Med Chem; 2006 Dec; 49(26):7731-9. PubMed ID: 17181155 [TBL] [Abstract][Full Text] [Related]
4. Structure-activity relationship studies of phenanthridine-based Bcl-XL inhibitors. Bernardo PH; Wan KF; Sivaraman T; Xu J; Moore FK; Hung AW; Mok HY; Yu VC; Chai CL J Med Chem; 2008 Nov; 51(21):6699-710. PubMed ID: 18925736 [TBL] [Abstract][Full Text] [Related]
5. Quinazoline sulfonamides as dual binders of the proteins B-cell lymphoma 2 and B-cell lymphoma extra long with potent proapoptotic cell-based activity. Sleebs BE; Czabotar PE; Fairbrother WJ; Fairlie WD; Flygare JA; Huang DC; Kersten WJ; Koehler MF; Lessene G; Lowes K; Parisot JP; Smith BJ; Smith ML; Souers AJ; Street IP; Yang H; Baell JB J Med Chem; 2011 Mar; 54(6):1914-26. PubMed ID: 21366295 [TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and computational studies of inhibitors of Bcl-XL. Park CM; Oie T; Petros AM; Zhang H; Nimmer PM; Henry RF; Elmore SW J Am Chem Soc; 2006 Dec; 128(50):16206-12. PubMed ID: 17165773 [TBL] [Abstract][Full Text] [Related]
7. Fragment-based deconstruction of Bcl-xL inhibitors. Barelier S; Pons J; Marcillat O; Lancelin JM; Krimm I J Med Chem; 2010 Mar; 53(6):2577-88. PubMed ID: 20192224 [TBL] [Abstract][Full Text] [Related]
8. (alpha/beta+alpha)-peptide antagonists of BH3 domain/Bcl-x(L) recognition: toward general strategies for foldamer-based inhibition of protein-protein interactions. Sadowsky JD; Fairlie WD; Hadley EB; Lee HS; Umezawa N; Nikolovska-Coleska Z; Wang S; Huang DC; Tomita Y; Gellman SH J Am Chem Soc; 2007 Jan; 129(1):139-54. PubMed ID: 17199293 [TBL] [Abstract][Full Text] [Related]
9. Targeting the BH3 domain mediated protein-protein interaction of Bcl-xL through virtual screening. Mukherjee P; Desai P; Zhou YD; Avery M J Chem Inf Model; 2010 May; 50(5):906-23. PubMed ID: 20392095 [TBL] [Abstract][Full Text] [Related]
10. Discovery of potent Mcl-1/Bcl-xL dual inhibitors by using a hybridization strategy based on structural analysis of target proteins. Tanaka Y; Aikawa K; Nishida G; Homma M; Sogabe S; Igaki S; Hayano Y; Sameshima T; Miyahisa I; Kawamoto T; Tawada M; Imai Y; Inazuka M; Cho N; Imaeda Y; Ishikawa T J Med Chem; 2013 Dec; 56(23):9635-45. PubMed ID: 24215352 [TBL] [Abstract][Full Text] [Related]
11. De novo design, synthesis and evaluation of benzylpiperazine derivatives as highly selective binders of Mcl-1. Ding X; Li Y; Lv L; Zhou M; Han L; Zhang Z; Ba Q; Li J; Wang H; Liu H; Wang R ChemMedChem; 2013 Dec; 8(12):1986-2014. PubMed ID: 24124106 [TBL] [Abstract][Full Text] [Related]
12. Isosteric exchange of the acylsulfonamide moiety in Abbott's Bcl-XL protein interaction antagonist. Dömling A; Antuch W; Beck B; Schauer-Vukasinović V Bioorg Med Chem Lett; 2008 Jul; 18(14):4115-7. PubMed ID: 18583128 [TBL] [Abstract][Full Text] [Related]
13. Identification of lead compounds as antagonists of protein Bcl-xL with a diversity-oriented multidisciplinary approach. Di Micco S; Vitale R; Pellecchia M; Rega MF; Riva R; Basso A; Bifulco G J Med Chem; 2009 Dec; 52(23):7856-67. PubMed ID: 19852471 [TBL] [Abstract][Full Text] [Related]
14. 3D-QSAR pharmacophore modeling and in silico screening of new Bcl-xl inhibitors. Almerico AM; Tutone M; Lauria A Eur J Med Chem; 2010 Nov; 45(11):4774-82. PubMed ID: 20728251 [TBL] [Abstract][Full Text] [Related]
15. Chelerythrine and sanguinarine dock at distinct sites on BclXL that are not the classic BH3 binding cleft. Zhang YH; Bhunia A; Wan KF; Lee MC; Chan SL; Yu VC; Mok YK J Mol Biol; 2006 Dec; 364(3):536-49. PubMed ID: 17011577 [TBL] [Abstract][Full Text] [Related]
16. Rational design and real time, in-cell detection of the proapoptotic activity of a novel compound targeting Bcl-X(L). Becattini B; Kitada S; Leone M; Monosov E; Chandler S; Zhai D; Kipps TJ; Reed JC; Pellecchia M Chem Biol; 2004 Mar; 11(3):389-95. PubMed ID: 15123268 [TBL] [Abstract][Full Text] [Related]
17. Aven, a novel inhibitor of caspase activation, binds Bcl-xL and Apaf-1. Chau BN; Cheng EH; Kerr DA; Hardwick JM Mol Cell; 2000 Jul; 6(1):31-40. PubMed ID: 10949025 [TBL] [Abstract][Full Text] [Related]
18. Rational design of new class of BH3-mimetics as inhibitors of the Bcl-xL protein. Pinto M; Orzaez Mdel M; Delgado-Soler L; Perez JJ; Rubio-Martinez J J Chem Inf Model; 2011 Jun; 51(6):1249-58. PubMed ID: 21528891 [TBL] [Abstract][Full Text] [Related]
19. Terephthalamide derivatives as mimetics of helical peptides: disruption of the Bcl-x(L)/Bak interaction. Yin H; Lee GI; Sedey KA; Rodriguez JM; Wang HG; Sebti SM; Hamilton AD J Am Chem Soc; 2005 Apr; 127(15):5463-8. PubMed ID: 15826183 [TBL] [Abstract][Full Text] [Related]
20. A new assay for the discovery of Bcl-XL inhibitors. Pisoni C; Cimoli G; Resconi A; Losi D; Lorenzetti R; Parodi S; Carrano L Farmaco; 2005; 60(11-12):938-43. PubMed ID: 16054143 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]